Advertisement

Dicerna Pharmaceuticals Inc. has added $4 million in a second close of its Series B financing, bringing the round to $29 million. The add-on funding was backed by new investor SR One, the independent corporate healthcare venture capital arm of GlaxoSmithKline.

As part of the financing, SR One partner Brian M. Gallagher Jr. will serve as an observer on Dicerna’s board of directors.

SOURCE

Advertisement
Advertisement